IC‐P‐088: Effects of 12 Months of Treatment with the PPARγ Agonist Rosiglitazone on Brain Glucose Metabolism in Alzheimer's Disease: A 18F‐FDG PET Study
Eugenii A. Rabiner,Sofia Tzimopoulou,Vincent J. Cunningham,Barbara Jeter,Marina Zvartau‐Hind,Mary Castiglia,Praful Mistry,Nick P. Bird,Julian Matthews,Brandon Whitcher,Thomas E. Nichols,Robert Lai,Narinder Lotay,Ann Saunders,Eric Reiman,Kewei Chen,Mike Gold,Paul M. Matthews
DOI: https://doi.org/10.1016/j.jalz.2009.05.642
2009-01-01
Abstract:Alzheimer's Disease (AD) leads to a progressive reduction of brain metabolism, which correlates with disease severity and is detectable with 18F-FDG PET, Rosiglitazone was demonstrated to have a favorable effect on cognitive function in AD1, 2. We assessed the effects of rosiglitazone on brain metabolism over a 12-month period in a pilot double-blind, placebo controlled, randomized parallel group study. Eighty patients with mild-to-moderate AD (MMSE 16-23) were randomized in a 1:1 ratio to receive a daily dose of either rosiglitazone (8 mg extended release), or placebo, and underwent four 18F-FDG PET scans (baseline, 1, 6 and 12 months) and three T1 weighted structural MRI (baseline, 6 and 12 months). Commonly used clinical inventories (ADAS-Cog, CIBIC+), specific cognitive domain tests, APOϵ4 genotype and a variety of plasma biomarkers were also collected. Dynamic PET emission data, and discrete venous blood 18F-FDG samples were used to calculate a cerebral metabolic rate for glucose index (CMRgluI) - a parameter directly proportional to brain glucose metabolism - in brain regions known to be involved in early stages of AD (Posterior Cingulate, Posterior Temporal, Parietal, Frontal, Medial Temporal), and the cerebellum. A GlobalGrey region comprising the whole brain grey matter was also assessed. Individual patient CMRgluI were analyzed using separate mixed-effects models for repeated measures, primary inference being changes at 12 months. Data from 78 patients were used in the analysis of the PET study. GMRgluI change was similar in all brain regions examined, hence the figures below refer to the GlobalGrey. The decline in CMRgluI in the rosiglitazone group was lower than in the placebo group at all points (6.3% vs 13.1%, 2. 6% vs. 7.1% and -1.5% vs 4.7% at 12, 6 and 1 months, respectively). However, group differences did not reach statistical significance (p = 0.17, 0.25 and 0.23 at 12, 6 and 1 months, respectively). No statistically significant differences were seen in the clinical assessments conducted. Subjects treated with Avandia XR showed a trend towards a lower rate of decline in CMRgluI compared to patients treated with placebo, but statistical significance was not reached.